



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

24 July 2015  
EMA/38583/2015  
Press Office

## Organisational matters

### CHMP meeting 20-23 July 2015

The main organisational topics addressed during the July meeting related to:

- Information on EMA survey to stakeholders on Type IBs, Type IIs and PSURs (human medicines). From April 2015, the Agency is undertaking a survey on some post-authorisation centralised procedures to help to improve regulatory processes and related guidance (see [external communication on EMA website](#)). Marketing Authorisations Holders are requested to provide their feedback on Type IBs, Type IIs and PSURs procedures with opinion/notifications from 1<sup>st</sup> April to 30<sup>th</sup> September 2015 by completing the following survey: <https://www.surveymonkey.com/r/7L3S3RS>.
- Discussion on the CHMP Work Plan topics for 2016.
- Information on the status of the IMI2 project ADAPT-SMART (**A**ccelerated **D**evelopment of **A**ppropriate **P**atient **T**herapies: a **S**ustainable, **M**ulti-stakeholder **A**pproach from **R**esearch to **T**reatment-outcomes). The ADAPT-SMART consortium will facilitate and accelerate the availability of Medicines Adaptive Pathways to Patients (MAPPs). MAPPs seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashion. The partners are public authorities and private companies. The project starts in July 2015 and the duration is 30 months.
- Nomination of Frank Holtkamp from Netherlands as observer to the Rheumatology/Immunology Working Party.

